Brain-sparing radiotherapy for neuroblastoma skull metastases

Pediatric Blood and Cancer

Volumn 50, Issue 6, 2008, Pages 1163-1168

  Wolden, Suzanne L ^a   Barker, Christopher A ^a   Kushner, Brian H ^a   Bodduluri, Haritha ^a   Della Biancia, Cesar ^a   Kramer, Kim ^a   Modak, Shakeel ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brain sparing; Local control; Neuroblastoma; Radiation oncology; Radiation therapy; Skull

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; FOLLOW UP; HEARING LOSS; HIGH RISK PATIENT; HUMAN; HYPOTHYROIDISM; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROBLASTOMA; PRIORITY JOURNAL; RADIODIAGNOSIS;

ADOLESCENT; ADULT; BRAIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NEUROBLASTOMA; RADIOTHERAPY DOSAGE; SKULL; SKULL NEOPLASMS;

EID: 42349095905     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21384     Document Type: Article

References (31)

1. Hutchinson R. On suprarenal sarcoma in children with metastases in the skull. Quart J Med 1907;1:31-38.
2. Sangthawan D, DesRosiers PM, Randall ME, et al. Relapse in the skull after myeloablative therapy for high-risk neuroblastoma. Pediatr Hematol Oncol 2003;20:23-30.
3. Alberts AS, Weich DJ, Anderson JD. Increased incidence of skull metastases in neuroblastoma. S Afr Med J 1984;66:62-63.
4. Deacon JM, Wilson PA, Peckham MJ. The radiobiology of human neuroblastoma. Radiother Oncol 1985;3:201-209.
5. Hall EJ, Marchese M, Hei TK, et al. Radiation response characteristics of human cells in vitro. Radiat Res 1988; 114: 415-424.
6. Wolden SL, Gollamudi SV, Kushner BH, et al. Local control with multimodality therapy for Stage 4 Neuroblastoma. Int J Radiat Oncol Biol Phys 2000;46:969-974.
7. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 2001;19:2821-2828.
8. Kushner BH, Kramer K, LaQuaglia MP, et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004;22:4888-4892.
9. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004;10:293-310.
10. Tofilon PJ, Fike JR. The radioresponse of the central nervous system: A dynamic process. Radiat Res 2000;153:357-370.
11. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31:2098-2103.
12. Brodeur GM, Pritchard J, Berthold J, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res 1994;383:363-369.
13. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over one year of age. J Clin Oncol 1994;12:2607-2613.
14. Cheung NK, Kushner BH, Cheung IY, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998;16:3053-3060.
15. Cheung NK, Kushner BH, LaQuaglia M, et al. N7: A novel multimodality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 2001;36:227-230.
16. Cheung IY, Lo Piccolo MS, Kushner BH, et al. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol 2003;21:3853-3858.
17. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000;18:2567-2575.
18. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006;24:669-676.
19. Lansky SB, List MA, Lansky LL, et al. The measurement of performance in childhood cancer patients. Cancer 1987;60:1651-1656.
20. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. pp 199-205.
21. Mor V, Laliberte L, Morris JN, et al. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984;53:2002-2007.
22. Paulino AC. Palliative radiotherapy in children with neuroblastoma. Pediatr Hematol Oncol 2003;20:111-117.
23. Deutsch M, Tersak JM. Radiotherapy for symptomatic metastases to bone in children. Am J Clin Oncol 2004;27:128-131.
24. Varma D, George N, Livingston J, et al. Acute visual loss as an early manifestation of metastatic neuroblastoma. Eye 2003;17:250-252.
25. Gunalp I, Gunduz K. Metastatic orbital tumors. Jpn J Ophthalmol 1995;39:65-70.
26. Ward JR, Feigenberg SJ, Mendenhall NP, et al. Radiation therapy for angiosarcoma. Head Neck 2003;25:873-878.
27. Laverdiere C, Cheung NK, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005;45:324-332.
28. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122.
29. Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006;107:417-422.
30. Chen WS, Jackson A, Budnick AS, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006;106:820-829.
31. Simon T, Hero B, Bongartz R, et al. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 year with residual local disease. Strahlenther Onkol 2006;182:389-394.